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Congenital leukemia is a rare event with a poor prognosis. We report a case of congenital leukemia with a
cryptic rearrangement of MLL demonstrable only with RT-PCR. Interestingly, with treatment, the patient
showed lineage plasticity of the leukemia with the development of monocytic lineage blasts after pre-
senting with B-cell lineage blasts. This was heralded by the development of a new clonal cytogenetic
abnormality. This case highlights the primitive nature of the leukemic cells in congenital leukemia, and
emphasizes that RT-PCR for MLL rearrangements may identify a subset of cases which are otherwise
negative by karyotyping, FISH, and chromosomal microarrays.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Leukemia which occurs in the ﬁrst month of life (congenital
leukemia) is a rare event, with an estimated incidence of 1 in
5 million births [1]. Congenital leukemias constitute a subset of
infant leukemia where a signiﬁcant percentage of cases show re-
arrangements involving the MLL (KMT2A) oncogene [2]. These
rearrangements presumably arise in utero, and this leukemia
subtype is notable for having the lowest somatic mutation burden
of any human malignancy measured thus far [3]. Despite this,
outcomes remain poor, and novel approaches to the treatment of
this leukemia are needed. We describe an unusual case of con-
genital leukemia with lineage switch following treatment, CNS
involvement, and a cryptic MLL rearrangement detectable only by
RT-PCR.2. Case study
A full term male was born to a 29-year-old G2P2 mother with
an unremarkable prenatal course. He was 7 pounds 14 ounces at
birth with normal APGAR scores at 1 and 5 min. On physical exam,
he was noted to have nodular purpuric lesions on his trunk andLtd. This is an open access article u
eles, 4650 Sunset Blvd., Los
ley).face, despite a non-traumatic delivery, and marked hepatosple-
nomegaly. A complete blood count showed a white blood cell
count (WBC) of 126 K/mL, hemoglobin of 16.7 g/dL, platelet count
of 23 K/mL, and 47% circulating lymphoblasts (Fig. 1A).
Flow cytometric immunophenotyping showed the circulating
blasts expressed CD19, CD20, CD22, CD24 partial, HLA -DR, CD34,
and TdT. There was variable expression of the myeloid markers
CD15 and CD33. The blasts were negative for CD3, CD10, MPO, and
all other T-cell, myeloid, and monocytic markers evaluated, in-
cluding CD14, CD64, and CD7 (Fig. 1C). A diagnosis of B-lympho-
blastic leukemia was made. Cytogenetics testing did not reveal any
karyotypic abnormalities, and FISH studies were negative for MLL
rearrangement (break apart probes), BCR-ABL fusion, ETV6-RUNX1
fusion, and showed disomy for chromosomes 4, 10 and 17. A cer-
ebrospinal ﬂuid sample taken at diagnosis was positive for lym-
phoblasts (700 WBC/mm3, 39% blasts; 64,000 RBC/mm3). Because
the lumber puncture was traumatic, the patient did not meet
criteria for CNS3 disease based on the Steinherz/Bleyer algorithm
where the CSF WBC/RBC needs to be greater than 2 times blood
WBC/RBC. Therefore, the patient was classiﬁed as CNS2c.
The patient received induction chemotherapy per modiﬁed
Children's Oncology Group (COG) infant ALL protocol AALL01P1
with dexamethasone, vincristine, and daunomycin at 50% of age-
adjusted infant doses; PEG-asparaginase, and intrathecal
methotrexate.
While induction chemotherapy resulted in clearance of the
peripheral lymphoblasts, a post-induction bone marrow evalua-
tion showed only a partial response with 15% residualnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A. Photomicrograph showing diagnostic specimen with lymphoblast morphology (Giemsa stain, 600X). B. Photomicrograph showing lineage switch specimen with
monoblast morphology (Giemsa stain, 600X). C. At diagnosis, the CD45 dim blasts (yellow) were CD19þ(shown), CD22þ , CD34þ , CD10- (shown), CD14- (shown), CD64-
(shown), CD7- (shown) and TdTþ(shown). D. With lineage shift, the blasts were CD19- (shown), CD34-, CD14þ(shown), CD64þ(shown), TdT- (shown), and CD7 partial
(shown; see text for details).
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given for an additional month (per St. Jude Infant Total XVI) which
included cyclophosphamide, cytarabine, and oral mercaptopurine.
The post-extended induction bone marrow evaluation still
showed 12% residual lymphoblasts (day þ66). Evaluation of the
blasts by ﬂow cytometry at both time points (þ35 and þ66)
showed an immunophenotype that was unchanged from the ori-
ginal diagnostic specimen.
Due to the suggestive immunophenotype and presentation, the
bone marrow was sent at the day þ66 time point for RT-PCR
evaluation of various MLL fusion transcripts. A positive result was
obtained for the presence of a MLL-MLLT1 t(11;19)(q23;q13) fu-
sion transcript. Despite the negative karyotyping and FISH results
for MLL rearrangements, the RT-PCR results suggested that a
cryptic MLL rearrangement was a driver in this neoplastic process.
He was then started on consolidation therapy per modiﬁed St.
Jude Infant Total XVI with vincristine, high dose methotrexate
(MTX) IV, and IT triples (MTX/ara-C/Hydrocortisone) with oral
6MP.
One month later the patient developed leukocytosis (WBC
46 K/mL) with 70% blasts and was re-induced to treat the persistent
B-lymphoblastic leukemia. A post re-induction bone marrow
performed at day þ130 found 6% lymphoblasts with the same
ﬂow cytometric immunophenotype found at diagnosis. However,karyotyping demonstrated a subset of cells with clonal evolution:
46, XY,þ6[2]/46, XY[18].
The chemotherapy was then modiﬁed to a regimen of vinor-
elbine, mitoxanthrone, dexamethasone and Bortezomib[4]. A bone
marrow evaluation following re-induction with the modiﬁed re-
gimen (day þ180) revealed 33% blasts, this time with monocytic
features by morphology (Fig. 1B). Rare lymphoblasts were also
present; cytochemical staining for MPO was negative in all blasts.
A repeat RT-PCR for t(11;19)(q23;p13) was again positive.
Flow cytometric immunophenotyping conﬁrmed the morpho-
logic impression of blast monocytic lineage; there was a small
subset of blasts with an immunophenotype consistent with the
original B-ALL, and a much larger subset of blasts expressing CD2
dim, CD4 partial, CD7, CD56, CD22 dim, CD13 partial, CD15, CD33,
CD117 partial, CD14, CD64, and CD38 bright. These blasts were
negative for CD19, CD10, CD24, and TdT, and expressed dim MPO,
an immunophenotype consistent with monocytic blasts (Fig. 1D).
A subsequent cerebrospinal ﬂuid (CSF) specimen demonstrated
signiﬁcant leukocytosis (36 WBC/mm3; 1 RBC/mm3) with 96%
promonocytes with atypical morphologic features, suggesting CNS
involvement by the lineage switched leukemia.
We performed chromosomal microarray analysis (CMA) ana-
lysis using CytoScan HD arrays from Affymetrics (Affymetrics,
Santa Clara, CA) on the patient's sample obtained at the time of
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deletions and duplications that may have arisen during the re-
arrangement which created the MLL-MLLT1 fusion detected by RT-
PCR. This analysis revealed a copy number gain (duplication), in-
volving the entire chromosome 6, which was consistent with the
presence of the clone with trisomy 6 observed by karyotyping. No
deletions or duplications were observed at the MLL and MLLT1
loci. Similarly, CMA analysis did not reveal any pathogenic, disease
associated copy number abnormalities (CNA) at other genomic
regions, consistent with the previously reported low CNA burden
in MLL-rearranged ALL in infants [5].
The patient was able to attain a MRD negative remission, as
determined by ﬂow cytometric immunophenotyping, following an
experimental infant relapse protocol at an outside facility. How-
ever, his chemotherapy course overall was marked by multiple
bacterial and fungal infections, and despite all therapeutic efforts,
the patient succumbed to infection at day þ320 of life and passed
away. He received a total anthracycline dose of 100 mg/m2 dau-
nomycin and 20 mg/m2 mitoxanthrone.3. Discussion
Congenital B-ALL is a rare disease with a poor prognosis, a high
rate of MLL rearrangements, and has a variable rate of CNS in-
volvement. In one recent study, there was only a 17% survival rate,
with 93% of patients having a detectable MLL rearrangement by
FISH or RT-PCR, and just 10% having CNS involvement [2]. Just a
handful of previous case reports and small case series have de-
scribed lineage switch in cases of congenital leukemia [6–12]. In-
terestingly, one case described a congenital leukemia with t
(11;19), with a lineage switch from lymphoid to monocytoid her-
alded by the acquisition of trisomy 6, as in the current case [9].
In the largest published case series, Rossi et al. identiﬁed seven
cases of infant B-ALL, including three cases of congenital leukemia,
with lineage switch from B-lymphoid to myelomonocytic leuke-
mia [12]. An additional two cases were described with a switch
from AML M5 to B-ALL. Of the nine described cases with lineage
switch, seven had detectable MLL rearrangements. These cases
were identiﬁed from 1482 cases of pediatric leukemia in the au-
thors’ institution, which suggested an incidence of 0.6%. A recent
meta-analysis of lineage switched pediatric leukemias identiﬁed
18 such cases reported, of which ﬁve were congenital acute leu-
kemia; all ﬁve had MLL rearrangements detectable [13].
RT-PCR positive, FISH negative MLL rearrangements have been
described previously [14]. Large scale recombinome studies of MLL
rearranged leukemia has identiﬁed a mechanism for such cases
which involves either a fragment of the MLL gene being inserted
elsewhere in the genome, or a fragment of a locus being inserted
proximally to the MLL gene [15]. Both circumstances would create
a copy-neutral MLL-fusion oncogene that would not be detectable
with break apart FISH testing or chromosomal microarrays.
Given the frequency of lineage switch association with MLL
rearrangements in congenital leukemia, every effort should be
made to thoroughly evaluate the MLL locus. In the present case,
MLL rearrangement was only detectable by RT-PCR. Because of
this, we would recommend RT-PCR for MLL rearrangements for all
cases of congenital acute leukemia which have normal karyotypes
and FISH results.
Submicroscopic deletions and duplications have been detected
by FISH and CMA analysis at breakpoints of apparently balanced
rearrangements that gave rise to abnormal gene fusions in leu-
kemia. Investigation of such submicroscopic CNAs can provide
insights into the nature and mechanisms of chromosomal re-
arrangements resulting in abnormal gene fusions. In addition,
CMA analysis allows genome-wide screening for acquired genomicalterations (CNAs and loss of heterozygosity) contributing to leu-
kemogenesis. In the current case, CMA did not detect alterations at
the MLL locus suggesting any changes at the locus were balanced
copy-neutral changes.
Mechanisms that would explain lineage switch have been
proposed and include a bipotential progenitor, de-differentiation,
and preferential proliferation of a minor clone not detectable at
diagnosis [12]. An interesting recent case of lineage switch invol-
ving a MLL rearranged infant leukemia, occurred following treat-
ment with CD19 directed chimeric antigen receptor T-cells [16]. In
this case, an IgH rearrangement present in the original leukemia
was not present in the relapsed myeloid blasts despite an identical
MLL rearrangement found in both. This suggests that a bipotential
progenitor with a germline IgH locus was the founder clone.
Outcomes are usually poor in congenital leukemia, and the
present case was no exception. New therapeutic efforts may pro-
vide increased efﬁcacy if targeted to the MLL rearranged oncogene
given the frequency of MLL rearrangements in congenital leuke-
mia. We speculate that the frequency of MLL rearrangements in
congenital leukemia may be higher than previously estimated due
to cryptic MLL rearrangements. In any case, the ﬁnding of lineage
plasticity in congenital leukemia predicts the presence of MLL
rearrangements.References
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